Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 55.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 53,574 shares of the company’s stock after selling 65,815 shares during the period. Aberdeen Group plc’s holdings in Centessa Pharmaceuticals were worth $1,299,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Campbell & CO Investment Adviser LLC purchased a new stake in Centessa Pharmaceuticals in the second quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company’s stock valued at $460,000 after acquiring an additional 33,854 shares during the last quarter. Meridian Wealth Partners LLC purchased a new position in shares of Centessa Pharmaceuticals during the second quarter worth $501,000. Finally, HighVista Strategies LLC raised its holdings in shares of Centessa Pharmaceuticals by 4.3% during the second quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock worth $535,000 after purchasing an additional 1,664 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 49,961 shares of company stock valued at $1,304,878. 7.09% of the stock is owned by company insiders.

Analyst Ratings Changes

CNTA has been the topic of several analyst reports. Guggenheim increased their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Oppenheimer raised their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Wells Fargo & Company boosted their price target on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Piper Sandler restated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Finally, Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Centessa Pharmaceuticals Stock Down 1.8%

CNTA stock opened at $24.50 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $30.58. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a 50-day simple moving average of $24.24 and a 200-day simple moving average of $23.30. The stock has a market capitalization of $3.29 billion, a P/E ratio of -13.39 and a beta of 1.56.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.